2014
An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation
Chaloupka FJ, Warner KE, Acemoğlu D, Gruber J, Laux F, Max W, Newhouse J, Schelling T, Sindelar J. An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation. Tobacco Control 2014, 24: 112. PMID: 25550419, PMCID: PMC4345832, DOI: 10.1136/tobaccocontrol-2014-052022.Peer-Reviewed Original ResearchConceptsEconomic impact analysisSound economic analysisNet economic benefitsImpact analysisProminent economistsSignificant regulatory actionsEconomic analysisDrug Administration's regulatory authorityNet benefitEconomic benefitsTobacco productsGraphic warning labelsRegulatory authoritiesLabel regulationsCostTobacco product regulationRegulatory actionProduct regulationEconomistsAuthoritiesBenefitsFuture analysesRulesControl ActJurisdictions
2013
Is research in substance abuse undervalued?
Sindelar JL, Strombotne KL. Is research in substance abuse undervalued? Addiction 2013, 109: 3-4. PMID: 24118168, DOI: 10.1111/add.12334.Peer-Reviewed Original Research
2012
Optimizing financial incentives to improve health among military personnel: Differences by pay grade and across branches
Sindelar JL, Torsiello N. Optimizing financial incentives to improve health among military personnel: Differences by pay grade and across branches. Preventive Medicine 2012, 55: s116-s117. PMID: 22673693, PMCID: PMC3641555, DOI: 10.1016/j.ypmed.2012.03.017.Peer-Reviewed Original Research
2010
Cost evaluation of evidence-based treatments.
Sindelar JL, Ball SA. Cost evaluation of evidence-based treatments. Addiction Science & Clinical Practice 2010, 5: 44-51. PMID: 22002453, PMCID: PMC3120119.Peer-Reviewed Original Research
2007
Clinic Variation in the Cost‐Effectiveness of Contingency Management
Olmstead TA, Sindelar JL, Petry NM. Clinic Variation in the Cost‐Effectiveness of Contingency Management. American Journal On Addictions 2007, 16: 457-460. PMID: 18058410, PMCID: PMC3072219, DOI: 10.1080/10550490701643062.Peer-Reviewed Original ResearchCost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease
Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS. Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease. JAMA Psychiatry 2007, 64: 1259-1268. PMID: 17984395, DOI: 10.1001/archpsyc.64.11.1259.Peer-Reviewed Original ResearchConceptsCost-benefit analysisSecond-generation antipsychoticsGreatest net health benefitNet benefit analysisNet health benefitWholesale priceHealth Utilities Index Mark 3Economic perspectiveAlzheimer's diseaseBenefit approachHealth care costsTotal health costsHealth costsQALYsCare costsMeasures of effectivenessPlacebo-controlled trialLower health care costsHealth service useTotal health careMeasures of functionCostTreatment of psychosisQuality of lifeSensitivity analysisCost‐effectiveness of prize‐based contingency management in methadone maintenance treatment programs
Sindelar JL, Olmstead TA, Peirce JM. Cost‐effectiveness of prize‐based contingency management in methadone maintenance treatment programs. Addiction 2007, 102: 1463-1471. PMID: 17645428, PMCID: PMC3072844, DOI: 10.1111/j.1360-0443.2007.01913.x.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisCounselingFemaleHumansMaleMethadoneNarcoticsPatient Acceptance of Health CareRewardSubstance-Related DisordersTreatment OutcomeConceptsPrize-based contingency managementUsual careContingency managementStimulant-negative urine samplesUrine samplesNational Drug Abuse Treatment Clinical Trials NetworkTreatment programMethadone maintenance treatment programIncremental costBaseline urine samplesMulti-site clinical trialMaintenance treatment programMethadone maintenance clinicsClinical Trials NetworkCommunity treatment programsCost-effectiveness studiesCost of treatmentCost-effectiveness analysisPresence of stimulantsCM conditionClinical trialsCommunity clinicsMaintenance clinicsEffectiveness trialTreatment outcomesThe cost‐effectiveness of four treatments for marijuana dependence
Olmstead TA, Sindelar JL, Easton CJ, Carroll KM. The cost‐effectiveness of four treatments for marijuana dependence. Addiction 2007, 102: 1443-1453. PMID: 17645430, PMCID: PMC2398724, DOI: 10.1111/j.1360-0443.2007.01909.x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCognitive Behavioral TherapyConnecticutCost-Benefit AnalysisCounselingFemaleHumansMaleMarijuana AbuseMotivationTreatment OutcomeConceptsMET/CBTDrug counselingContingency managementPatient outcomesYoung adultsEffective treatmentMarijuana dependenceAcceptability curvesIncremental cost-effectiveness ratioRandomized clinical trialsCost of therapyPatient outcome measuresCost-effective dependsCost-effectiveness ratioSubstance abuse clinicsCost-effective treatmentCM procedureClinical trialsOutcome measuresUrine specimenUrine specimensAdditional weeksAdditional studiesMarijuana abstinenceLonger durationWhat do we get for our money? Cost‐effectiveness of adding contingency management
Sindelar J, Elbel B, Petry NM. What do we get for our money? Cost‐effectiveness of adding contingency management. Addiction 2007, 102: 309-316. PMID: 17222286, DOI: 10.1111/j.1360-0443.2006.01689.x.Peer-Reviewed Original Research
2006
Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia
Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. American Journal Of Psychiatry 2006, 163: 2080-2089. PMID: 17151158, DOI: 10.1176/ajp.2006.163.12.2080.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsChronic DiseaseCost-Benefit AnalysisDrug CostsFollow-Up StudiesHealth Care CostsHumansLongitudinal StudiesMiddle AgedPatient DropoutsPerphenazinePsychiatric Status Rating ScalesQuality-Adjusted Life YearsResearch DesignSchizophreniaSchizophrenic PsychologyTreatment OutcomeCost-effectiveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs
Olmstead TA, Sindelar JL, Petry NM. Cost-effectiveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs. Drug And Alcohol Dependence 2006, 87: 175-182. PMID: 16971054, PMCID: PMC1950254, DOI: 10.1016/j.drugalcdep.2006.08.012.Peer-Reviewed Original ResearchConceptsUsual careStimulant abusersClinical trialsPatient outcomesNational Drug Abuse Treatment Clinical Trials NetworkDrug abuse treatment clinicsAbstinence-based incentivesIncremental cost-effectiveness ratioUsual care groupPrimary patient outcomeRandomized clinical trialsClinical Trials NetworkPsychosocial treatment programCost-effectiveness ratioCost-effectiveness analysisCare groupTreatment clinicsStimulant abstinenceAcceptability curvesAbstinence timeTreatment programTrials NetworkIncremental costCareIncentive group
2004
Value to smokers of improved cessation products: Evidence from a willingness-to-pay survey
Busch S, Falba T, Duchovny N, Jofre-Bonet M, O'Malley S, Sindelar J. Value to smokers of improved cessation products: Evidence from a willingness-to-pay survey. Nicotine & Tobacco Research 2004, 6: 631-639. PMID: 15370159, DOI: 10.1080/14622200410001727885.Peer-Reviewed Original ResearchMeSH KeywordsAdultCost-Benefit AnalysisFemaleFinancing, PersonalHealth Care CostsHealth SurveysHumansMaleMiddle AgedMotivationSmokingSmoking CessationConceptsSmoking cessation productsSmoking cessationCessation productsCessation treatmentEffective smoking cessation treatmentsWeight gainTobacco cessation treatmentSmoking cessation treatmentPresent studyClinical trialsEffective treatmentBaseline surveyCessationTreatmentNew HavenMedicationsSmokersTrialsCreating an aggregate outcome index: Cost-effectiveness analysis of substance abuse treatment
Sindelar J, Jofre-Bonet M. Creating an aggregate outcome index: Cost-effectiveness analysis of substance abuse treatment. The Journal Of Behavioral Health Services & Research 2004, 31: 229-241. PMID: 15263863, DOI: 10.1007/bf02287287.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisData CollectionHumansOutcome Assessment, Health CarePhiladelphiaSubstance-Related DisordersUnited KingdomCost effectiveness of disulfiram Treating cocaine use in methadone-maintained patients
Jofre-Bonet M, Sindelar JL, Petrakis IL, Nich C, Frankforter T, Rounsaville BJ, Carroll KM. Cost effectiveness of disulfiram Treating cocaine use in methadone-maintained patients. Journal Of Substance Use And Addiction Treatment 2004, 26: 225-232. PMID: 15063917, PMCID: PMC3662046, DOI: 10.1016/s0740-5472(04)00004-2.Peer-Reviewed Original ResearchConceptsMethadone treatmentClinical trialsCocaine useDouble-blind clinical trialCocaine dependenceStandard methadone treatmentBlind clinical trialMethadone-maintained patientsRandomized clinical trialsOpioid-dependent subjectsMethadone-maintained opiate addictsStandard treatmentOutcome measuresOpioid addictsPromising treatmentOpiate addictsIncremental costDisulfiramAdditional treatmentNumber of daysTrialsTreatmentCost effectivenessEconomic evaluationAddicts
2003
Economic Costs of Influenza-Related Work Absenteeism
Akazawa M, Sindelar JL, Paltiel AD. Economic Costs of Influenza-Related Work Absenteeism. Value In Health 2003, 6: 107-115. PMID: 12641861, DOI: 10.1046/j.1524-4733.2003.00209.x.Peer-Reviewed Original ResearchMeSH KeywordsAbsenteeismAdultCost-Benefit AnalysisDecision TreesFemaleHumansInfluenza VaccinesInfluenza, HumanMaleMiddle AgedRegression AnalysisUnited StatesWorkplaceConceptsNet benefitEconomic costsMedical Expenditure Panel Survey Household ComponentMean productivity costsAverage work lossDollar termsUS dollarsEmployment dataProductivity impactEconomic attractivenessNumber of workdaysWorking-age peopleHousehold ComponentProductivity costsWorker productivityWorker absenteeismEmployment factorsSimple frameworkInfluenza-like illnessDecision analysisReduced absenteeismCostBaseline analysisInfluenza vaccinationTerms of absence
2002
Benefit‐Cost Analysis of Addiction Treatment: Methodological Guidelines and Empirical Application Using the DATCAP and ASI
French MT, Salomé HJ, Sindelar JL, McLellan AT. Benefit‐Cost Analysis of Addiction Treatment: Methodological Guidelines and Empirical Application Using the DATCAP and ASI. Health Services Research 2002, 37: 433-455. PMID: 12036002, PMCID: PMC1430361, DOI: 10.1111/1475-6773.031.Peer-Reviewed Original ResearchConceptsDrug Abuse Treatment Cost Analysis ProgramBenefit-cost analysisEconomic evaluationEconomic benefitsFuture economic researchTotal economic benefitTotal economic costFuture economic evaluationsEconomic researchDetailed methodological guidelinesEmpirical applicationConsecutive fiscal yearsSensitivity analysisOutpatient drug-free programsEconomic costsMethodological guidelinesFiscal yearCost dataSubsequent sensitivity analysisDrug-free programsResource useMethodological foundationsBenefitsCostEstimates
2001
INNOVATIONS IN TREATMENT FOR DRUG ABUSE: Solutions to a Public Health Problem
Sindelar J, Fiellin D. INNOVATIONS IN TREATMENT FOR DRUG ABUSE: Solutions to a Public Health Problem. Annual Review Of Public Health 2001, 22: 249-272. PMID: 11274521, DOI: 10.1146/annurev.publhealth.22.1.249.ChaptersConceptsPublic health problemEffectiveness of treatmentIllicit drug useDrug useHealth problemsDrug dependenceBroader social costsImportant public health problemNew pharmacological agentsFuture treatment programsIndividual functioningStandard treatmentPharmacological agentsTreatment programDrug abuseCounseling strategiesPrevention effortsHigh dropout rateTreatmentFunctioningCompletion ratesDropout rateLow completion ratesLow effectivenessNew setting
1991
Economic cost of illicit drug studies: critique and research agenda.
Sindelar JL. Economic cost of illicit drug studies: critique and research agenda. NIDA Research Monograph 1991, 113: 33-45. PMID: 1762641.Peer-Reviewed Original Research